Published in Proc Natl Acad Sci U S A on September 27, 2010
Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. Cell (2014) 1.75
Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res (2013) 1.72
A Drosophila model of high sugar diet-induced cardiomyopathy. PLoS Genet (2013) 1.28
Glucose metabolism and cardiac hypertrophy. Cardiovasc Res (2011) 1.28
O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol (2012) 1.16
O-GlcNAc signaling entrains the circadian clock by inhibiting BMAL1/CLOCK ubiquitination. Cell Metab (2013) 1.14
Protein O-linked β-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol (2011) 1.14
Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev Proteomics (2013) 1.12
O-GlcNAc modification of NFκB p65 inhibits TNF-α-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS One (2011) 1.11
Roles of glucose in photoreceptor survival. J Biol Chem (2011) 1.09
Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ Heart Fail (2014) 1.08
Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation. PLoS One (2011) 1.03
High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure. PLoS One (2013) 1.02
Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. Stem Cells (2013) 0.99
Protein O-GlcNAcylation and cardiovascular (patho)physiology. J Biol Chem (2014) 0.98
O-GlcNAc and the cardiovascular system. Pharmacol Ther (2013) 0.98
The roles of O-linked β-N-acetylglucosamine in cardiovascular physiology and disease. Am J Physiol Heart Circ Physiol (2012) 0.97
Responses of hypertrophied myocytes to reactive species: implications for glycolysis and electrophile metabolism. Biochem J (2011) 0.96
Enhanced cardiac protein glycosylation (O-GlcNAc) of selected mitochondrial proteins in rats artificially selected for low running capacity. Physiol Genomics (2012) 0.96
Overview: the maturing of proteomics in cardiovascular research. Circ Res (2011) 0.95
Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res (2014) 0.95
Cardiac overexpression of 8-oxoguanine DNA glycosylase 1 protects mitochondrial DNA and reduces cardiac fibrosis following transaortic constriction. Am J Physiol Heart Circ Physiol (2011) 0.95
Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology. Crit Rev Biochem Mol Biol (2014) 0.94
MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression. J Biol Chem (2014) 0.93
Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci (2012) 0.92
Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent. J Biol Chem (2012) 0.90
Protein quality control and metabolism: bidirectional control in the heart. Cell Metab (2015) 0.90
Metabolic remodeling in the hypertrophic heart: fuel for thought. Circ Res (2012) 0.89
Cardiomyocyte Ogt is essential for postnatal viability. Am J Physiol Heart Circ Physiol (2013) 0.88
Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart. Cardiovasc Diabetol (2013) 0.87
Removal of Abnormal Myofilament O-GlcNAcylation Restores Ca2+ Sensitivity in Diabetic Cardiac Muscle. Diabetes (2015) 0.86
High glucose induces mitochondrial dysfunction independently of protein O-GlcNAcylation. Biochem J (2015) 0.84
O-GlcNAcylation and oxidation of proteins: is signalling in the cardiovascular system becoming sweeter? Clin Sci (Lond) (2012) 0.83
Utilization of fluorescent probes for the quantification and identification of subcellular proteomes and biological processes regulated by lipid peroxidation products. Free Radic Biol Med (2012) 0.82
Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med (2015) 0.82
Glucose Transporters in Cardiac Metabolism and Hypertrophy. Compr Physiol (2015) 0.82
Proteomic analysis of physiological versus pathological cardiac remodeling in animal models expressing mutations in myosin essential light chains. J Muscle Res Cell Motil (2015) 0.80
Reduced cardiac fructose 2,6 bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction. PLoS One (2013) 0.80
How exercise may amend metabolic disturbances in diabetic cardiomyopathy. Antioxid Redox Signal (2015) 0.80
Induction of activating transcription factor 3 limits survival following infarct-induced heart failure in mice. Am J Physiol Heart Circ Physiol (2015) 0.79
Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. J Am Heart Assoc (2013) 0.78
O-GlcNAcylation Negatively Regulates Cardiomyogenic Fate in Adult Mouse Cardiac Mesenchymal Stromal Cells. PLoS One (2015) 0.78
Z-band alternatively spliced PDZ motif protein (ZASP) is the major O-linked β-N-acetylglucosamine-substituted protein in human heart myofibrils. J Biol Chem (2012) 0.78
Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol (2017) 0.78
A New Method to Stabilize C-Kit Expression in Reparative Cardiac Mesenchymal Cells. Front Cell Dev Biol (2016) 0.77
Finding the missing link between the unfolded protein response and O-GlcNAcylation in the heart. Circ Res (2014) 0.76
Cardioprotection in ischaemia-reperfusion injury: novel mechanisms and clinical translation. J Physiol (2015) 0.76
Cardiomyocyte Ogt limits ventricular dysfunction in mice following pressure overload without affecting hypertrophy. Basic Res Cardiol (2017) 0.76
E2F1 Transcription Factor Regulates O-linked N-acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Expression. J Biol Chem (2015) 0.75
Fuel availability and fate in cardiac metabolism: A tale of two substrates. Biochim Biophys Acta (2016) 0.75
The role of O-GlcNAc transferase in regulating the gene transcription of developing and failing hearts. Future Cardiol (2014) 0.75
O-GlcNAcylation and cardiovascular disease. Biochem Soc Trans (2017) 0.75
A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition. Heart Fail Rev (2017) 0.75
Integration of flux measurements to resolve changes in anabolic and catabolic metabolism in cardiac myocytes. Biochem J (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr (1990) 25.24
Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature (2007) 8.48
Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res (2001) 6.15
Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab (2005) 4.65
The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci U S A (2000) 4.55
Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science (2001) 4.13
Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature (2008) 3.98
Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation (2002) 3.11
Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A (2006) 2.71
Metabolic gene expression in fetal and failing human heart. Circulation (2001) 2.59
Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol (2004) 2.56
O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell (2003) 2.51
Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol (2003) 2.32
Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem (2003) 2.24
Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol (1994) 2.15
Heart failure and protein quality control. Circ Res (2006) 2.15
Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A (2003) 1.62
O-GlcNAc signaling in the cardiovascular system. Circ Res (2010) 1.43
O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function. Circ Res (2008) 1.32
Effects of diabetes and hyperglycemia on the hexosamine synthesis pathway in rat muscle and liver. Diabetes (1995) 1.29
The intracellular accumulation of UDP-N-acetylhexosamines is concomitant with the inability of human colon cancer cells to differentiate. J Biol Chem (1985) 1.22
New insights into metabolic signaling and cell survival: the role of beta-O-linkage of N-acetylglucosamine. J Pharmacol Exp Ther (2008) 1.09
Hypothalamic malonyl-CoA triggers mitochondrial biogenesis and oxidative gene expression in skeletal muscle: Role of PGC-1alpha. Proc Natl Acad Sci U S A (2006) 1.07
Deficiency of iNOS does not attenuate severe congestive heart failure in mice. Am J Physiol Heart Circ Physiol (2004) 1.06
Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Am J Physiol Heart Circ Physiol (2006) 0.95
Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A (2005) 3.64
Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation (2009) 2.61
Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation (2008) 2.37
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J Am Coll Cardiol (2003) 2.23
Mitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. Mol Cell Biol (2011) 2.23
IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res (2004) 2.12
Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation (2008) 2.11
Post-transcriptional gene silencing of KChIP2 and Navbeta1 in neonatal rat cardiac myocytes reveals a functional association between Na and Ito currents. J Mol Cell Cardiol (2008) 2.09
Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res (2006) 1.98
Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol (2008) 1.95
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res (2002) 1.90
Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. Circ Res (2003) 1.89
A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol (2011) 1.79
Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy. J Mol Cell Cardiol (2011) 1.69
H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation (2013) 1.65
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation (2010) 1.64
Mechanism of myocardial ischemia with an anomalous left coronary artery from the right sinus of Valsalva. J Thorac Cardiovasc Surg (2012) 1.56
Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res (2013) 1.54
Cardiomyocyte deletion of mitofusin-1 leads to mitochondrial fragmentation and improves tolerance to ROS-induced mitochondrial dysfunction and cell death. Am J Physiol Heart Circ Physiol (2011) 1.53
Downregulation of CuZn-superoxide dismutase contributes to beta-adrenergic receptor-mediated oxidative stress in the heart. Cardiovasc Res (2007) 1.51
Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury. Circ Res (2008) 1.50
Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res (2002) 1.46
A novel subcutaneous counterpulsation device: acute hemodynamic efficacy during pharmacologically induced hypertension, hypotension, and heart failure. Artif Organs (2010) 1.46
Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation (2006) 1.45
Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res (2010) 1.45
Bioenergetic function in cardiovascular cells: the importance of the reserve capacity and its biological regulation. Chem Biol Interact (2010) 1.45
Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res (2002) 1.43
O-GlcNAc signaling in the cardiovascular system. Circ Res (2010) 1.43
Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure. Am J Physiol Heart Circ Physiol (2007) 1.39
Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. J Mol Cell Cardiol (2008) 1.36
Protein glutathiolation by nitric oxide: an intracellular mechanism regulating redox protein modification. FASEB J (2006) 1.34
WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal (2010) 1.28
Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem (2008) 1.26
Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes. Amino Acids (2010) 1.26
Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am J Physiol Heart Circ Physiol (2008) 1.25
Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res (2003) 1.23
Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction. J Mol Cell Cardiol (2010) 1.23
Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med (2003) 1.20
O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am J Physiol Heart Circ Physiol (2009) 1.20
Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am J Physiol Heart Circ Physiol (2002) 1.18
O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol (2012) 1.16
Mitofusins 1 and 2 are essential for postnatal metabolic remodeling in heart. Circ Res (2012) 1.16
Differential actions of cardioprotective agents on the mitochondrial death pathway. Circ Res (2003) 1.14
O-GlcNAc signaling entrains the circadian clock by inhibiting BMAL1/CLOCK ubiquitination. Cell Metab (2013) 1.14
Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun (2004) 1.14
Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol (2002) 1.13
Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol (2010) 1.11
Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury. J Biol Chem (2009) 1.11
Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway. Circulation (2003) 1.10
New insights into metabolic signaling and cell survival: the role of beta-O-linkage of N-acetylglucosamine. J Pharmacol Exp Ther (2008) 1.09
Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. J Mol Cell Cardiol (2008) 1.09
PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. Biochem J (2013) 1.07
Heart transplant vs left ventricular assist device in heart transplant-eligible patients. Ann Thorac Surg (2011) 1.06
Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits. Circulation (2005) 1.06
Standardized bioenergetic profiling of adult mouse cardiomyocytes. Physiol Genomics (2012) 1.06
EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling. J Mol Cell Cardiol (2010) 1.05
Microfluidic cardiac cell culture model (μCCCM). Anal Chem (2010) 1.05
Hemodynamic responses to continuous versus pulsatile mechanical unloading of the failing left ventricle. ASAIO J (2010) 1.04
Endothelial cell culture model for replication of physiological profiles of pressure, flow, stretch, and shear stress in vitro. Anal Chem (2011) 1.03
The late phase of preconditioning and its natural clinical application--gene therapy. Heart Fail Rev (2007) 1.02
Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol (2014) 1.01
Delayed adaptation of the heart to stress: late preconditioning. Stroke (2004) 1.01
Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. J Am Coll Cardiol (2012) 1.00
TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J Pharmacol Exp Ther (2010) 0.99
Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. Stem Cells (2013) 0.99
Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J Mol Cell Cardiol (2011) 0.97
Responses of hypertrophied myocytes to reactive species: implications for glycolysis and electrophile metabolism. Biochem J (2011) 0.96
Mitofusins are required for angiogenic function and modulate different signaling pathways in cultured endothelial cells. J Mol Cell Cardiol (2011) 0.96
The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning. PLoS One (2012) 0.96
Cardiac overexpression of 8-oxoguanine DNA glycosylase 1 protects mitochondrial DNA and reduces cardiac fibrosis following transaortic constriction. Am J Physiol Heart Circ Physiol (2011) 0.95
Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Am J Physiol Heart Circ Physiol (2006) 0.95
Tumor necrosis factor receptor 2 signaling limits β-adrenergic receptor-mediated cardiac hypertrophy in vivo. Basic Res Cardiol (2011) 0.94
Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol (2011) 0.94
Diabetic Cardiomyopathy in OVE26 Mice Shows Mitochondrial ROS Production and Divergence Between In Vivo and In Vitro Contractility. Rev Diabet Stud (2007) 0.94
Endothelial cell overexpression of fas ligand attenuates ischemia-reperfusion injury in the heart. J Biol Chem (2003) 0.93
Ouabain stimulates protein kinase B (Akt) phosphorylation in opossum kidney proximal tubule cells through an ERK-dependent pathway. Am J Physiol Cell Physiol (2007) 0.92
Ouabain induces cell proliferation through calcium-dependent phosphorylation of Akt (protein kinase B) in opossum kidney proximal tubule cells. Am J Physiol Cell Physiol (2006) 0.92
Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol (2004) 0.92
Intraoperative evaluation of the HeartMate II flow estimator. J Heart Lung Transplant (2008) 0.91
Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond. Basic Res Cardiol (2011) 0.91
Strategies for developing biomarkers of heart failure. Clin Chem (2003) 0.91
Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits. Am J Physiol Heart Circ Physiol (2002) 0.90